American Heart Journal Plus, 2022 Study objective: The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol guideline recommends a maximally-tolerated statin with add-on lipid-lowering therapy, ezetimibe and/or proprotein convertase subtilisin/kexin type 9
Chibuike J. Alanaeme +14 more
doaj +1 more source
Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg)::Design and Rationale of the ODYSSEY OPTIONS Studies [PDF]
, 2014 The phase 3 ODYSSEY OPTIONS studies (OPTIONS I, NCT01730040; OPTIONS II, NCT01730053) are multicenter, multinational, randomized, double-blind, active-comparator, 24-week studies evaluating the efficacy and safety of alirocumab, a fully human monoclonal ...
Peter H. Jones +13 more
core +1 more source
Cardiology Research and Practice, 2020 Risk factors for cardiovascular disease such as hypertension and hyperlipidemia are associated with cognitive decline. However, there is still no clear evidence that the use of antihypertensive or lipid-lowering therapy can prevent or delay cognitive ...
Ze-Min Kuang
doaj +1 more source
Lipid-lowering for lower limb atherosclerosis [PDF]
, 2007 Background: Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease. It may also reduce cardiovascular events and/or local disease progression in people with lower limb peripheral arterial disease (PAD ...
Price, Jackie +9 more
core +1 more source
Cardiovascular Diabetology, 2017 Background Dyslipidaemia is a major contributor to the increased risk of cardiovascular disease (CVD) associated with type 2 diabetes (T2D). This study aimed to characterize the extent of lipid-lowering therapy use and its impact on lipid and glycaemic ...
Markolf Hanefeld +3 more
doaj +1 more source
PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
Reviews in Cardiovascular Medicine, 2022 Lipid-lowering therapy is of great importance in reducing the burden of atherosclerotic cardiovascular disease. Statins act as first-line therapy in the current lipid management guidelines.
Ying Xiao +7 more
doaj +1 more source
Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview [PDF]
Diabetes & Metabolism Journal, 2023 Dyslipidemia is a potentially modifiable cardiovascular risk factor. Whereas the recommendations for the treatment target of dyslipidemia in the general population are being more and more rigorous, the 2013 Kidney Disease: Improving Global Outcomes ...
Sang Heon Suh, Soo Wan Kim
doaj +1 more source
Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importnace of Lp(a) [PDF]
, 2012 We carried out a genome-wide association study (GWAS) of LDL-c response to statin using data from participants in the Collaborative Atorvastatin Diabetes Study (CARDS; n = 1,156), the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT; n = 895), and the ...
Postmus, Iris +65 more
core +1 more source
Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus [PDF]
, 2013 Purpose: This paper reports the results of an audit that assessed the prevalence of residual hypertriglyceridemia and the potential need for intensified management among patients with statin-treated type 2 diabetes mellitus (T2DM) in primary care in the ...
Greener, Mark +2 more
core +1 more source
Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings [PDF]
, 2019 Background: Cardiovascular diseases (CVDs) are the main complication leading to morbidity and mortality among patients with type 2 diabetes mellitus (T2DM).
Elnaem, Mohamed Hassan Abdelaziz +3 more
core +2 more sources